Back to Search
Start Over
First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study.
- Source :
- Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p250-250, 185p
- Publication Year :
- 2024
Details
- Language :
- English
- ISSN :
- 0732183X
- Volume :
- 42
- Database :
- Supplemental Index
- Journal :
- Journal of Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 174954344
- Full Text :
- https://doi.org/10.1200/JCO.2024.42.3_suppl.250